Santa Casa de Misericórdia de Porto Alegre, Departamento de Nefrologia e Transplante de Rim e Pâncreas, Porto Alegre, RS, Brasil.
Universidade Federal de Ciências da Saúde de Porto Alegre, Programa de Pós-Graduação em Patologia, Porto Alegre, RS, Brasil.
J Bras Nefrol. 2021 Oct-Dec;43(4):520-529. doi: 10.1590/2175-8239-JBN-2020-0189.
Tuberculosis (TB) is a prevalent infection after kidney transplantation (KT) in high-burden countries. Latent tuberculosis infection (LTBI) screening includes previous TB history, chest radiograph findings, and tuberculin test (TST) and/or interferon-gamma release assays (IGRAs) results. We aimed to compare our routine LTBI screening of KT candidates and living donors (LD) with their IGRA results, and evaluate if this would improve isoniazid (INH) treatment referral.
We evaluated adult KT candidates and LD with complete routine LTBI screening and QuantiFERON-TB® Gold In-Tube (QFT) testing. Blood samples were collected from April 4th, 2014 to October 31st, 2018, with follow-up until October 31st, 2019.
There were 116 KT recipients, with 30% QFT-positive results. Positive QFT was associated with past TB history (p=0.007), positive TST (p<0.0001), residual radiographic lesions (p=0.003), and diabetes (p=0.035). There were 25 LD, 40% had positive QFT. Positive QFT was associated with a positive TST (p=0.002). Positive QFT results increased INH referral in 80%. Post-transplant TB incidence was 2.6% in a median follow-up of 2 (1-33) months. No variables were associated with post-transplant TB. TB patients had inferior, although non-significant, 5-year graft survival (66.7% vs. 76.5%) (p = 0.402).
In the present study, the association of QFT to our routine LTBI screening incremented INH treatment referral, but there was still a high incidence of post-transplant TB, possibly related to other forms of infection, such as new exposure and donor transmission.
结核病(TB)是高负担国家肾移植(KT)后常见的感染。潜伏性结核感染(LTBI)筛查包括既往 TB 病史、胸片结果以及结核菌素试验(TST)和/或干扰素-γ释放试验(IGRAs)结果。我们旨在比较 KT 候选人和活体供者(LD)的常规 LTBI 筛查与 IGRA 结果,并评估这是否会改善异烟肼(INH)治疗推荐。
我们评估了接受完整常规 LTBI 筛查和 QuantiFERON-TB® Gold In-Tube(QFT)检测的成年 KT 候选人和 LD。血样采集于 2014 年 4 月 4 日至 2018 年 10 月 31 日,随访至 2019 年 10 月 31 日。
共有 116 例 KT 受者,其中 30%的 QFT 阳性结果。QFT 阳性与既往 TB 病史(p=0.007)、TST 阳性(p<0.0001)、残留放射学病变(p=0.003)和糖尿病(p=0.035)相关。有 25 例 LD,40%的 QFT 阳性。QFT 阳性与 TST 阳性相关(p=0.002)。QFT 阳性结果使 INH 推荐增加了 80%。中位随访 2(1-33)个月内,移植后 TB 发生率为 2.6%。没有变量与移植后 TB 相关。TB 患者的 5 年移植物存活率虽然较低,但无统计学意义(66.7%比 76.5%)(p=0.402)。
在本研究中,QFT 与我们的常规 LTBI 筛查的关联增加了 INH 治疗推荐,但移植后 TB 的发生率仍然很高,这可能与其他形式的感染有关,如新暴露和供体传播。